e-Drug3D

2193
M ELINZANETANT


INN
ELINZANETANT

(is an active metabolite) (has an active metabolite)

cas 3055971-15-5
CLASS

GENITO
NEUROKININ 1 (NK1) AND NEUROKININ 3 (NK3) RECEPTOR ANTAGONIST
TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE
ROUTE (list)

-

ATC code

G02CX07
PK parameters

Tmax 2 HOUR (PMID39719488)
t1/2 34.2 HOUR (PMID39719488)

 Target

TARGET NEUROKININ 1 (NK1)
NEUROKININ 3 (NK3)

 DrugCentral

-

 Download SDF file Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-hexahydro-3-hydroxy-7-(hydroxymethyl)pyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl]-N,alpha,alpha-trimethyl-3,5-bis(trifluoromethyl)- (ACI)

Formula:
C33H35F7N4O4

Calculated chemical properties:

MW 684.65
NB_atoms 48
XLogP 5.37
PSA 84.481
NB_HD 2
NB_HA 8
fsp3 0.45
Lipinski(0=no;1=yes) 0

FDA
-

 Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL
e-Drug3D

2192
M ELINZANETANT


INN
ELINZANETANT

(is an active metabolite) (has an active metabolite)

cas 3055971-14-4
CLASS

GENITO
NEUROKININ 1 (NK1) AND NEUROKININ 3 (NK3) RECEPTOR ANTAGONIST
TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE
ROUTE (list)

-

ATC code

G02CX07
PK parameters

Tmax 1.75 HOUR (PMID39719488)
t1/2 41.2 HOUR (PMID39719488)

 Target

TARGET NEUROKININ 1 (NK1)
NEUROKININ 3 (NK3)

 DrugCentral

-

 Download SDF file Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-hexahydro-3-hydroxy-7-(hydroxymethyl)pyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl]-N,alpha,alpha-trimethyl-3,5-bis(trifluoromethyl)- (ACI)

Formula:
C33H35F7N4O4

Calculated chemical properties:

MW 684.65
NB_atoms 48
XLogP 5.24
PSA 84.85
NB_HD 2
NB_HA 8
fsp3 0.45
Lipinski(0=no;1=yes) 0

FDA
-

 Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL
e-Drug3D

2194
M ELINZANETANT


INN
ELINZANETANT

(is an active metabolite) (has an active metabolite)

cas 3055971-15-5
CLASS

GENITO
NEUROKININ 1 (NK1) AND NEUROKININ 3 (NK3) RECEPTOR ANTAGONIST
TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE
ROUTE (list)

-

ATC code

G02CX07
PK parameters

Tmax 2 HOUR (PMID39719488)
t1/2 34.2 HOUR (PMID39719488)

 Target

TARGET NEUROKININ 1 (NK1)
NEUROKININ 3 (NK3)

 DrugCentral

-

 Download SDF file Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-hexahydro-3-hydroxy-7-(hydroxymethyl)pyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl]-N,alpha,alpha-trimethyl-3,5-bis(trifluoromethyl)- (ACI)

Formula:
C33H35F7N4O4

Calculated chemical properties:

MW 684.65
NB_atoms 48
XLogP 5.37
PSA 86.374
NB_HD 2
NB_HA 8
fsp3 0.45
Lipinski(0=no;1=yes) 0

FDA
-

 Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL
e-Drug3D

2195
M ELINZANETANT


INN
ELINZANETANT

(is an active metabolite)

cas 3055971-16-6
CLASS

GENITO
NEUROKININ 1 (NK1) AND NEUROKININ 3 (NK3) RECEPTOR ANTAGONIST
TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE
ROUTE (list)

-

ATC code

G02CX07
PK parameters

Tmax 2 HOUR (PMID39719488)
t1/2 31.3 HOUR (PMID39719488)

 Target

TARGET NEUROKININ 1 (NK1)
NEUROKININ 3 (NK3)

 DrugCentral

-

 Download SDF file Benzeneacetamide, N-[4-[4-fluoro-2-(hydroxymethyl)phenyl]-6-[(7S,9aS)-hexahydro-3-hydroxy-7-(hydroxymethyl)pyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl]-N,alpha,alpha-trimethyl-3,5-bis(trifluoromethyl)- (ACI)

Formula:
C33H35F7N4O5

Calculated chemical properties:

MW 700.65
NB_atoms 49
XLogP 4.56
PSA 104.478
NB_HD 3
NB_HA 9
fsp3 0.45
Lipinski(0=no;1=yes) 0

FDA
-

 Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL
e-Drug3D

2196
M ELINZANETANT


INN
ELINZANETANT

(is an active metabolite)

cas 3055971-16-6
CLASS

GENITO
NEUROKININ 1 (NK1) AND NEUROKININ 3 (NK3) RECEPTOR ANTAGONIST
TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE
ROUTE (list)

-

ATC code

G02CX07
PK parameters

Tmax 2 HOUR (PMID39719488)
t1/2 31.3 HOUR (PMID39719488)

 Target

TARGET NEUROKININ 1 (NK1)
NEUROKININ 3 (NK3)

 DrugCentral

-

 Download SDF file Benzeneacetamide, N-[4-[4-fluoro-2-(hydroxymethyl)phenyl]-6-[(7S,9aS)-hexahydro-3-hydroxy-7-(hydroxymethyl)pyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl]-N,alpha,alpha-trimethyl-3,5-bis(trifluoromethyl)- (ACI)

Formula:
C33H35F7N4O5

Calculated chemical properties:

MW 700.65
NB_atoms 49
XLogP 4.56
PSA 106.248
NB_HD 3
NB_HA 9
fsp3 0.45
Lipinski(0=no;1=yes) 0

FDA
-

 Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL